Catalog No.
DHD17403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a-kappa
Clonality
Monoclonal
Target
Epithelial glycoprotein 314, hEGP314, Major gastrointestinal tumor-associated protein GA733-2, EGP314, TACSTD1, Adenocarcinoma-associated antigen, TROP1, EPCAM, Epithelial glycoprotein, KS 1/4 antigen, Tumor-associated calcium signal transducer 1, M4S1, CD326, Ep-CAM, EGP, Epithelial cell adhesion molecule, M1S2, KSA, Cell surface glycoprotein Trop-1, GA733-2, Epithelial cell surface antigen, MIC18
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16422
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
17-1A, CAS: 156586-89-9
Clone ID
Edrecolomab
Edrecolomab (monoclonal antibody 17-1A), PMID: 9806108
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma, PMID: 11578913
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study, PMID: 12241873
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, PMID: 29295696
Edrecolomab in the adjuvant treatment of colorectal carcinoma, PMID: 12517501
Edrecolomab in the adjuvant treatment of colorectal carcinoma, PMID: 12517502
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer, PMID: 11273586
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma, PMID: 12743982
Technology evaluation: edrecolomab, Centocor Inc, PMID: 11249762
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study, PMID: 15933423
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581, PMID: 21747085
Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells, PMID: 12176782
The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study, PMID: 15713997
Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow, PMID: 10632331
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies, PMID: 21044305
A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer, PMID: 11182031
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer, PMID: 19273708
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab, PMID: 19273695
[Anti-cancer monoclonal antibody], PMID: 15861718
EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs, PMID: 29329202
Marketed therapeutic antibodies compendium, PMID: 22531442
Recent developments in colorectal cancer treatment by monoclonal antibodies, PMID: 17049015
Adjuvant therapy of colon cancer, PMID: 15726511
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment, PMID: 12115595
Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition, PMID: 29667344
Immunomodulation therapy in colorectal carcinoma, PMID: 10814560
[Adjuvant therapy for colon cancer], PMID: 15497107
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges, PMID: 17325709
EpCAM: A new therapeutic target for an old cancer antigen, PMID: 14508099
Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials, PMID: 29966444
Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer, PMID: 16955700
Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy, PMID: 15933417
Monoclonal antibodies in the treatment of colorectal cancer, PMID: 15177487
Monoclonal antibodies as therapeutic agents for cancer, PMID: 15120666
Antibody-targeted immunotherapy for treatment of malignancy, PMID: 11160771
Monoclonal and bispecific antibodies as novel therapeutics, PMID: 16648969
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside, PMID: 20426706
Adjuvant therapy for colon cancer in the new millenium, PMID: 12705552
Monoclonal antibodies in the treatment of cancer, Part 2, PMID: 12966906
Monoclonal antibodies in the treatment of cancer, Part 1, PMID: 12951753
Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer, PMID: 12445374
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance), PMID: 27432924
Immunotherapy for colorectal cancer, PMID: 11122811
EpCAM as a target in cancer therapy, PMID: 20385979
Expression of EpCAM in uveal melanoma, PMID: 17125516
[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review], PMID: 21129296
EpCAM: a potential antimetastatic target for gastric cancer, PMID: 19941073
[Clinical assessment of monoclonal antibodies for the treatment and diagnosis of colorectal cancers], PMID: 11904970
Current concepts in immunotherapy for the treatment of colorectal cancer, PMID: 12018689
Novel immunologic and biologic therapies for breast cancer, PMID: 11122896
For research use only. Not for human or drug use.
